# Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

> **NCT01173679** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 10 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** dasatinib
- **DRUG:** Rituximab
- **DRUG:** fludarabine

## Key facts

- **NCT ID:** NCT01173679
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2017-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01173679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01173679, "Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01173679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*